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ABSTRACT: In this work, we brought together two existing
clinical techniques used in cancer treatmentX-ray radiation and
photodynamic therapy (PDT), whose combination termed X-PDT
uniquely allows PDT to be therapeutically effective in deep tissue.
To this end, we developed mitochondrially targeted biodegradable
polymer poly(lactic-co-glycolic acid) nanocarriers incorporating a
photosensitizer verteporfin, ultrasmall (2−5 nm) gold nano-
particles as radiation enhancers, and triphenylphosphonium acting
as the mitochondrial targeting moiety. The average size of the
nanocarriers was about 160 nm. Upon X-ray radiation our
nanocarriers generated cytotoxic amounts of singlet oxygen within
the mitochondria, triggering the loss of membrane potential and mitochondria-related apoptosis of cancer cells. Our X-PDT strategy
effectively controlled tumor growth with only a fraction of radiotherapy dose (4 Gy) and improved the survival rate of a mouse
model bearing colorectal cancer cells. In vivo data indicate that our X-PDT treatment is cytoreductive, antiproliferative, and
profibrotic. The nanocarriers induce radiosensitization effectively, which makes it possible to amplify the effects of radiation. A
radiation dose of 4 Gy combined with our nanocarriers allows equivalent control of tumor growth as 12 Gy of radiation, but with
greatly reduced radiation side effects (significant weight loss and resultant death).
■ INTRODUCTION
Rectal cancer accounts for approximately 30% of colorectal
cancers and is one of the most frequent cancers in
industrialized countries.1,2 Surgical resection remains the
mainstay treatment in patients with rectal cancer. However,
some Stage II and a significant proportion of Stage III rectal
cancer patients undergo neoadjuvant radiotherapy or chemo-
radiotherapy to downsize the primary tumor and lymph nodes
and to reduce rates of local recurrence after surgery.3
Unfortunately, the side effect of this standard of care treatment
is progressive late morbidity due to high doses (45 Gy) in
long-course radiotherapy4 and systematic toxicity of chemo-
drugs used in chemo-radiotherapy. Therefore, it is important
to find new methods for downsizing tumors, using lower
radiation levels, and, potentially, obviating the use of
chemotherapy as a radiosensitizer.
In this work, we test novel mitochondrially targeted
nanoparticles, designed to have cytostatic/cytoreductive
effects, applied to the neoadjuvant treatment of rectal cancer.
Our approach is based on X-ray-induced photodynamic
therapy (X-PDT).5 Conventional PDT is a clinically approved
therapeutic procedure that is used for the treatment of
superficial lesions.6 In PDT, visible light is combined with
photosensitizers (Photofrin, Levulan, Visudyne, or alterna-
tives) causing the generation of cytotoxic singlet oxygen or
other reactive oxygen species (ROS) that lead to cell death and
vascular shutdown.6−8 The PDT agents can also be effectively
stimulated by limited, clinically safe doses of radiation (X-
rays).9,10 These X-rays easily penetrate through body tissues,
allowing X-PDT to overcome the ∼1 cm tissue depth
limitation of the conventional PDT.11,12 Both PDT and
radiotherapy have been independently applied in clinical
practice, paving the way for the accelerated medical translation
of X-PDT.
Intracellular localization of photosensitizer molecules is of
crucial importance for the effectiveness of PDT.13,14
Specifically, mitochondria have been found to be suitable
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subcellular targets for ROS generated by PDT.15,16 The ROS-
induced effects are capable of disrupting cellular function such
as proliferation,17 while mitochondrial DNA damage initiates
diverse cell death mechanisms.18 Consequently, mitochondria-
targeted PDT has proven to be more effective than a
nontargeted alternative, allowing greater specificity and
potentially smaller effective drug doses. We therefore explored
the efficacy of X-PDT with mitochondrially targeted nano-
constructs based on biodegradable poly(lactic-co-glycolic acid)
(PLGA) polymer. PLGA is approved by the US FDA and
European Medicines Agency as a drug delivery system for
different medical applications such as carrying photosensitizers
to tumor cells.4,19,20 Verteporfin (VP), a photosensitizer, and
ultrasmall (2−5 nm) colloidal gold nanoparticles were
incorporated into this polymer nanocarrier platform (Figure
1A). VP is an efficient photosensitizer which has been clinically
approved for PDT in neovascular macular degeneration.21,22 It
has been demonstrated to generate ROS at low doses of X-ray
radiation.10,23 Gold nanoparticles were chosen to increase X-
ray-induced ROS generation as they strongly interact with X-
ray radiation due to their radiation enhancement prop-
erty,24−26 and because of our earlier finding of increased
singlet oxygen (1O2) generation from VP in the presence of
gold nanoparticles.23 The nanocarrier surface was modified
with triphenylphosphonium (TPP), a molecule able to target
the inner mitochondrial membrane attributed to its strong
lipophilic and cationic nature.27,28 This effect is expected to be
stronger in cancer cells due to their lower mitochondrial
membrane potential compared to normal cells (∼−220 mV vs
∼−140 mV).29 We tested our nanocarriers in in vitro settings
and a preclinical xenograft model of colorectal cancer. The in
vitro cytotoxicity effect of X-PDT was demonstrated by
assessing the viability and apoptosis in colorectal cancer cells.
The signaling mechanisms underlying the anticancer effect
were investigated via Western blot analyses. Additionally, the
tumor control effect was investigated by monitoring tumor
development in mice bearing colorectal cancer xenografts and
via histological and biochemical analyses of tumor tissues after
treatment.
■ RESULTS AND DISCUSSION
Characterization of PLGA Nanocarriers and PLGA−
TPP Conjugates. A typical scanning electron microscope
(SEM) image was taken of PLGA nanoparticles loaded with
VP and gold nanoparticles (Figure 1B), with the average size of
∼160 nm determined by dynamic light scattering (DLS, Figure
S4). The gold nanoparticles loaded inside PLGA were clearly
observed under transmission electron microscopy (TEM) with
high magnification (Figure 1B). TPP conjugation on the
surface of PLGA nanocarriers was confirmed by different ζ
potentials of PLGA−VP and PLGA−TPP in water (Figure
1C) and ultraviolet−visible (UV−vis) absorption spectra
containing the typical peaks of TPP at 250 and 278 nm
(Figure 1D). We calculated the amount of gold loaded inside
PLGA nanoparticles by measuring the concentration of the
gold ion based on inductively coupled plasma mass
spectrometry (ICP-MS) data and comparing this to a standard
curve of a gold ion solution with a known concentration. We
also determined the average number of gold nanoparticles per
Figure 1. (A) Schematic illustration of X-ray-induced PDT via PLGA nanocarriers incorporating verteporfin (VP) and gold nanoparticles. (B) SEM
image of PLGA nanocarriers; inset is a TEM image of the same sample under high magnification. The gold nanoparticles were clearly observed
under TEM with high magnification. (C) ζ potential of PLGA−VP and PLGA−TPP. (D) Absorption spectra of PLGA samples with and without
TPP conjugation. (E) Percentage increase of SOSG fluorescence intensities in PLGA samples with different molar ratios of gold and VP under X-
ray radiation at different doses. ** p < 0.01, *** p < 0.001 determined by Student t-test, n = 3.
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PLGA nanoparticle based on the total number of gold
nanoparticles and PLGA in the same sample, which is
estimated to be approximately 244 (in the case of gold: VP
= 5:1). The average number of TPP conjugated to each
nanocarrier surface was also calculated based on absorbance of
TPP attached to the PLGA nanocarriers and a standard curve
of absorbance versus concentration of carboxyl−TPP solution
(Figure S5), which was approximately 176.
The generation of 1O2 is a key factor in X-ray-induced PDT.
1O2 generation was confirmed by using singlet oxygen sensor
green (SOSG) and monitoring the enhancement of
fluorescence intensity at 488 nm excitation. In this study, we
varied the amount of gold nanoparticles loaded inside PLGA
and checked the 1O2 production under these conditions. As
shown in Figure 1E, the 1O2 enhancement was similar in these
PLGA samples with and without gold nanoparticles at 1 and 2
Gy radiation. At 4 Gy radiation, PLGA loaded with gold
nanoparticles and VP (molar ratio of gold and VP was 5:1 and
10:1) demonstrated a higher ability to generate 1O2, compared
to PLGA nanocarrier-loaded VP alone, with respective 126%
and 95% increases in SOSG fluorescence intensity. For
comparison purposes, we also checked if pure PLGA alone
and PLGA loaded with gold nanoparticles alone can generate
the sufficient amount of 1O2 under the same conditions. Our
findings indicated that PLGA alone did not affect 1O2
generation, compared with other PLGA samples. Taken
together, we chose PLGA nanocarriers with a molar ratio of
gold and VP of 5:1 for further cell and animal experimentation.
To increase the stability of the PLGA nanocarrier in the
physiological environment, we used PLGA−polyethylene
glycol (PEG) polymer for nanocarrier fabrication. The serum
stability of PLGA nanocarriers was assessed based on the total
amount of VP released from the nanocarriers (Figure S6).
Different amounts of VP were released from non-PEGylated
PLGA nanocarriers during incubation, with the total amount
being 27% at 48 h when incubated in phosphate-buffered
saline (PBS) with 10% (v/v) fetal bovine serum (FBS). By
contrast, in the case of PEGylated PLGA nanocarriers, the VP
release profile was obviously reduced, with 10% and 15% of VP
Figure 2. Intracellular 1O2 generation indicated by SOSG fluorescence signal in HCT116 cells obtained (A) immediately and (B) 24 h after the
treatments indicated in the images. (C) Real-time detection of ΔΨm in HCT116 cells after treatment with PLGA−TPP in combination with 4 Gy
radiation at the time points indicated in the images. The membrane potential differences are indicated by the ratio of red versus green fluorescence
intensities in the cells. Scale bar is 50 μm. *** indicates a significant difference between groups (p < 0.001) as determined by Student t-test, n = 4.
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released from PLGA at 48 h, suspended in PBS containing 10%
FBS and 50% FBS, respectively. These findings imply that
PEGylation of the PLGA could maintain the amount of loaded
VP and ensure the maximal ROS generated from VP
predominantly located within the nanocarriers.
Assessment of Mitochondria-Targeting Capability of
PLGA−TPP Conjugates, Intracellular 1O2 Generation,
and Mitochondria Membrane Potential (ΔΨm). The
mitochondria-targeting capabilities of the PLGA−TPP con-
jugates incorporating VP (TPP−PLGA−VP) were investigated
by incubating the nanocarriers with HCT116 cells using
nontargeted PLGA as a control. The confocal microscopy
analysis of the cells treated with TPP−PLGA−VP showed
greater uptake activity than nonconjugated ones in the
mitochondria of the cells (Figure S7). Quantitative analysis
using the ImageJ/Fiji “colocalization analysis” function
revealed greater colocalization of the PLGA−TPP with
MitoTracker Green in the mitochondria of the cells (Pearson’s
correlation coefficient, PCC = 0.76). For the nonconjugated
PLGA nanocarriers, a lower value (PCC = 0.40) was obtained
as demonstrated by the different position of the red signals of
VP and the mitochondrial green staining. We also assessed the
colocalization between TPP-conjugated nanoparticles and
lysosomes and found a PCC of 0.31. Such improved
mitochondrial uptake of PLGA−TPP nanocarriers is attributed
to the high lipophilicity of the TPP targeting ligand30 and the
positive charge induced by TPP, which was also apparent from
the ζ potential values.
We further assessed intracellular 1O2 generation using the
SOSG probe whose fluorescent signal can be observed after
treatment.31 As shown in Figure 2A, a weakly fluorescent
SOSG signal was observed immediately after the treatments.
Among these treatment conditions, the cells treated with X-
ray-triggered PLGA−TPP conjugates and PLGA nanocarriers
demonstrated similarity in SOSG fluorescence intensity,
indicating that a similar amount of 1O2 was generated under
these two conditions. However, SOSG fluorescence observed
under these two conditions showed a significantly higher signal
(higher amount of intracellular 1O2 generation) compared with
other treatments including PLGA nanocarriers, PLGA−TPP
nanocarriers, and X-ray radiation at 4 Gy. At 24 h, the SOSG
signal from the cells treated with PLGA−TPP nanocarriers in
combination with 4 Gy was significantly elevated (4.8-fold)
compared to the control group, indicating the sufficient
amount of singlet oxygen induced by X-ray-triggered PLGA−
TPP (Figure 2B and Figure S8 at 2 and 4 h). We also noticed
that the SOSG signal in the cells treated with X-ray-triggered
PLGA was lower than that with the X-ray-triggered PLGA−
Figure 3. (A−D) Flow cytometry plots showing distribution of annexin-V vs 7-AAD staining after different treatments on HCT 116 cells using the
Muse Annexin V and Dead Cell Assay. (E) % of cells and the mean percentages ± SD of apoptosis (early and late apoptosis) of three independent
experiments. (F) Western blotting analyses of the expressions of proteins involved in the cell proliferation and apoptosis in HCT 116 cells that
received different treatments as indicated. (G−J) Densitometric analysis of the protein bands shown in part F. Values represent the means ±
standard deviation of three experiments. * p < 0.05, *** p < 0.001 as determined by Student t-test.
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TPP. Such difference in the capacity to generate singlet oxygen
between X-ray-triggered PLGA and PLGA−TPP may have its
root in the fact that mitochondria require higher oxygen levels
for production of ATP used to provide the cell’s energy.32,33
The higher oxygen environment in mitochondria enabled
enhanced 1O2 production from VP molecules once they were
delivered to the mitochondria by TPP−PLGA nanocarriers.
The loss of ΔΨm is commonly observed after toxicant
exposure (such as singlet oxygen), leading to cell death by
apoptosis and necrosis. Herein, we investigated whether
mitochondria were affected by the treatments describe above.
JC-1 staining (a mitochondrial membrane potential dye) was
used to evaluate the alterations in ΔΨm in HCT116 cells after
the treatments. Time-dependent reduction of the JC-1 red/
green fluorescence ratio was observed (Figure 2C), with a
significantly lower ratio observed at 1 h after treatment and
over the next 24 h compared with immediate detection. We
also analyzed the ΔΨm at 24 h after other treatment
conditions. The results shown in Figure S9 revealed that
these experimental conditions had a smaller effect on ΔΨm,
compared to mitochondria-targeted X-ray-induced PDT (p <
0.001). Taken together, the PLGA−TPP nanocarriers that
previously showed the highest localization in the mitochondria
and the greatest 1O2 production under 4 Gy radiation also
exhibited the largest ΔΨm toxicity in HCT116 cells in
combination with 4 Gy, compared to other treatment
modalities.
Evaluation of Cell Viability and Apoptosis after X-
PDT. To assess cell viability following the treatments, cytotoxic
effects were tested by MTS assay. The toxicity of PLGA−TPP
alone and X-ray radiation alone on HCT 116 and normal
colon CCD 841 cells was low, with about 90% viability
compared to the control groups. However, when these two
treatments were combined, a significant decrease in cancer cell
survival was observed (Figure S10). To assess the proapoptotic
effect of X-PDT, an Annexin V assay was performed in
HCT116 cells. The representative flow cytometry plots show
proportions of four groups HCT116 cells after different
treatments (Figure 3A−D). A significant increase in the
number of apoptotic cells from 5.3 ± 1.8% to 37.4 ± 4.7% after
treatment with X-PDT was observed compared with the
control group. By contrast, only 8.9 ± 2.9% and 7.8 ± 3.5%
rates of apoptosis were, respectively, detected after treatments
with nanoparticles and X-rays alone (Figure 3E). These
findings indicate that most of the antiproliferative activity of X-
PDT in cell cultures is mediated by apoptosis.
To elucidate the mechanism of X-PDT-mediated apoptosis,
we investigated the expression of proteins involved in cell
growth and apoptosis in HCT116 cells using Western blot
analyses. We first checked the effect of X-PDT in the Akt/ERK
signaling pathway, which plays an important role in the
proliferation of many types of cancer cells, including colorectal
cancer cells.34,35 As shown in Figure 3G,H, the phosphor-
ylation levels of both Akt (P-Akt) and ERK (P-ERK) proteins
were decreased in the cells treated with the PLGA−TPP in
combination with 4 Gy, compared to other conditions. We also
measured the apoptosis-related protein (BAX, BAD, Bcl-2 and
caspase-3) expression levels after the treatments (Figure 3F).
BAX and BAD regulate apoptosis mainly at the level of the
mitochondria.36 Caspase is also an important apoptosis inducer
that exists on the outer membranes of mitochondria.37 As
shown in Figure 3J, X-PDT promotes the expression of BAX
Figure 4. Tumor control of X-PDT in a xenograft model of colorectal cancer. (A) Changes in tumor volume after various treatments as indicated;
repeated measures two-way ANOVA statistical analysis with Tukey multiple comparison test was used to determine differences between treatment
groups, * p < 0.05 indicates significant difference between the groups (4 Gy vs 4 Gy and PLGA−TPP; PLGA−TPP vs 4 Gy and PLGA−TPP). (B)
A Kaplan−Meier curve reveals that treatment with X-PDT extended the survival of mice bearing colorectal cancer. Black arrow indicates the time of
treatment administration. (C) Photographs of tumors isolated at the end point. Tumor size and survival data were plotted using GraphPad prism
v7.0.
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and BAD and reduced antiapoptotic protein (Bcl-2)
expression. It also significantly activates caspase-3 compared
with other treatment conditions (Figure 3I). In combination
with our findings on ΔΨm, these data support that cell
apoptosis triggered by X-PDT could involve the mitochondrial
signaling pathway in our study.
Anticancer Effect of X-ray-Induced PDT in Vivo.
Having confirmed that X-PDT induced cellular cytotoxicity
in HCT116 cells, we hypothesized that mitochondria-targeted
PLGA−TPP nanocarriers would reduce tumor growth when
combined with low-dose X-ray radiation. Accordingly, we
treated a subcutaneous mouse model bearing human HCT116
colorectal cells with PLGA−TPP nanocarrier alone, X-ray
alone, and X-PDT. As displayed in Figure 4A, although the
group treated with X-PDT (4 Gy and PLGA−TPP) did not
show significant differences in the tumor size, compared with
the control group, the survival curve demonstrated a significant
difference between these two groups (log-rank test, p = 0.013,
Figure 4B). The X-PDT group shows evidence of a significant
control of tumor growth, compared with other treatment
conditions (X-PDT vs 4 Gy, p = 0.031; X-PDT vs PLGA−
TPP, p = 0.042, Tukey’s test). Furthermore, the mice exposed
to this combined treatment had a significantly increased
survival (Figure 4B), compared with other treatment
conditions (log-rank test, p = 0.0019, control; p = 0.0018, 4
Gy; p = 0.0027, PLGA−TPP; p = 0.049, 8 Gy). In contrast,
mice treated with either 4 Gy (p = 0.79) or PLGA−TPP alone
(p = 0.55) did not have a survival difference compared with the
control group. This shows that individual treatment modalities
(4 Gy alone and nanocarriers alone) did not have measurable
impacts on tumor growth in vivo.
We also assessed tumor response to a high radiation dose,
with two groups treated with 8 and 12 Gy radiation. In the case
of animals treated with 8 Gy radiation, 2 out of 5 animals died
within 2 weeks due to tumor overgrowth, while all 5 animals in
the X-PDT group survived over the same period. The mice
treated with a single 12 Gy radiation dose did not show
significant differences in the tumor growth compared with X-
PDT during the experimental period (Figure 4A); however,
they experienced significant weight loss after irradiation
(Figure S12), leading to the death of 2 out of 4 animals
within 2 weeks. Taken together, these results suggest that our
X-PDT at 4 Gy treatment has a broadly similar therapeutic
effect as 12 Gy of radiation. The tumor size data in mice
exposed to different treatments are presented in Figure 4C.
Evaluation of Histological Outcomes of Anticancer
Therapy. Effect of X-PDT on Volume of Tumor Tissue. We
carried out a quantitative analysis of the relative amount of live
and dead tissue in the tumors, calculated as a product of live/
dead tumor tissue area percentage and the total volume of the
tumor at the end point (Figure 5A and Figure S13). The
results indicate that the relative average area of live tumor
tissue seen in the histological sections was similar across the
studied groups (55−65%, Figure 5C). Interestingly, in the X-
PDT group the volume of live tumor tissue was only about a
factor 2 higher than the initial grafting volume (100 mm3),
while in other groups the volume of live tissue in the tumors
during the experimental period increased by a factor of
between 4.7 and 6 (Figure 5D). This indicates that the X-PDT
treatment was cytoreductive. No statistically significant
increase in the dead tumor tissue volume was observed in
any group (Figure S14). Considering a relative decrease of the
overall tumor volume in the X-PDT group vs other groups, we
Figure 5. (A) Left image: example of a scanned image of a whole-sample section applied for further color segmentation. The image demonstrates
two halves of the same tumor and the areas of different tissue structure. T, live tumor tissue featuring intensive staining with hematoxylin; N,
necrotic and paranecrotic areas in the central part of the tumors notable by enhanced eosinophilic and reduced basophilic staining; C, artificial
cavities in the tumors reflecting the areas with mucous content; F, peritumoral fibrotic capsule. Right image: example of automated classification of
the live tumor tissue in the samples (shown in white color). (B) Average number of Ki-67-positive cells per field of view in the histological
specimens of the tumors. Error bars represent lower and upper boundaries of CI 95% for the mean. (C) Relative amount of live tumor tissue on the
histological sections in the studied groups. (D) Calculated volume of live tumor tissue in the tumor samples from studied groups, n = 5 in each
group.
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attribute the tumor shrinking to cytostatic or profibrotic effects
of X-PDT or accelerated tumor growth/edema in control
groups.
Investigation of Cellular Origins of Tissue Effects in X-
PDT. We carried out an analysis of mitotic activity and fibrotic
changes to shed light on the origin of the observed decrease in
tumor volume and the relative volume of live tumor tissue in
the X-PDT group. We found that X-PDT induced a statistically
significant decrease in mitotic activity (lower expression of Ki-
67) in the tumor tissue, in comparison to controls. Treatment
with X-rays and nanocarriers alone also induced a moderate
cytostatic effect; however, there was no statistical difference
between treatments (Figure 5B and Figure S15). The degree of
fibrotic reaction in the tumors in different groups was
evaluated by Masson’s trichrome method. We observed signs
of fibrotic transformation of the peritumoral tissue in the X-
PDT group, and accumulation of collagen in the central
necrotic area was more pronounced in X-PDT than in other
groups (Figure 6A). The results of the Kruskall−Wallis test
show that the volume of the peritumoral fibrotic capsule and
collagen accumulation in the capsule and in the central
necrotic area were different between the studied groups
(Figure 6B−D). The relative areas of fibrotic and cancer tissue
were evaluated semiquantitatively (Table S1). Treatment with
PLGA−TPP contributed to an increase of the volume of the
peritumoral fibrotic capsule and accumulation of collagen in
the central necrotic area, in comparison to the control group (p
= 0.006 and p = 0.034, respectively; Mann−Whitney test).
Treatment with X-PDT enhanced all examined signs of fibrosis
in comparison to controls, with high statistical significance (p <
0.001 in all the cases). The profibrotic effect of PLGA−TPP
was stronger than the effect of the X-ray treatment alone, but
less pronounced than the effect of X-PDT (p < 0.001 for all
examined cases). Although fibrotic changes were observed
most frequently in the X-PDT group, such fibrotic trans-
formation of the tumor in a short time (less than 8 weeks) after
X-ray radiation was not considered as a side effect, but as a
therapeutic effect and a sign of tumor regression.38 This is in
the agreement with the significant reduction of the tumor
volume revealed in the X-PDT group (Figure 4) which cannot
be explained completely by the cytostatic effect of the
treatment only due to the absence of statistically significant
difference in Ki-67 staining between the PLGA-TPP, 4 Gy, and
X-PDT groups (Figure 5B). These findings collectively imply
that the therapeutic benefit of the X-PDT treatment is a
combinatorial effect of cytoreductive and profibrotic action,
where tumor fibrosis contributes to shrinkage of the damaged
tumor tissue.
■ CONCLUSION
In this work we applied a novel X-PDT treatment to colorectal
cancer cells and a mouse model of colorectal cancer using a
Figure 6. (A) Top image: peritumoral capsule and periphery of the tumor with visible accumulation of aligned collagen fibers (blue staining).
Bottom image: accumulation of nonorganized collagen in the central necrotic area of the tumor. The histograms for fibrotic feature distributions
based on (B) fibrotic capsule volume, (C) fibrotic capsule collagen staining intensity, and (D) collagen staining intensity in the central necrotic
area. “0” indicates the absence of fibrotic signs, and “3” indicates obvious fibrotic transformation.
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nanocarrier delivery platform based on the clinically approved
PLGA polymer, the photosensitizer VP, and ultrasmall gold
nanoparticles (sized below the renal clearance threshold (2−5
nm)). This represents an advance as earlier studies in the area
of X-PDT employed poorly biocompatible scintillating nano-
materials. These nanomaterials convert X-ray photons to
visible photons further activating a nearby photosensitizer to
produce ROS.39−41 In contrast, we established that visible
photons are not necessary because a clinically approved
photosensitizer, VP, can be directly activated by low-dose X-
ray radiation. To optimize the effectiveness of nanocarriers
against the vulnerable organelle, we used mitochondrial
targeting of nanocarriers with a TPP molecule. The cellular
mitochondria were damaged by 1O2 generated in X-PDT, as
shown through their loss of mitochondrial membrane
potential. Singlet oxygen also initiated apoptosis, leading to
rapid damage to cancer cells. The ΔΨm loss (Figure 2C), in
vitro cytotoxicity (Figure 3), and the induction of apoptosis
pathways (Figure 3) were clear indicators of the cellular effects
of 1O2. We further validated the in vivo antitumor effect of X-
PDT by testing it in a subcutaneous mouse xenograft model
bearing colorectal cancer cells. The tumor response was
evaluated by comparing tumor growth in mice treated with X-
PDT, nanocarriers alone, and X-rays at 4 Gy alone.
Significantly inhibited tumor growth was observed in the
group treated with the combined treatment compared with
other groups (Figure 4). Such tumor control is consistent with
decreased proliferation, as indicated by the reduced phosphor-
ylation of Akt and ERK (Figure 3F), reduced expression of
Ki67 protein (Figure 5B), and enhanced fibrosis (Figure 6)
observed in the mouse group treated with X-PDT. We found
evidence of apoptotic pathways contributing to cell death in X-
PDT as apparent from increased levels of BAX and BAD and
reduced level of Bcl-2 in cells (Figure 3F).
Cytotoxicity of X-PDT attainable through a synergistic
action of X-ray radiation and PDT represents a radio-
sensitization mechanism which makes it possible to amplify
the effects of radiation. We found that the radiation dose of 4
Gy combined with TPP−PLGA nanocarriers allows equivalent
control of tumor growth as 12 Gy, but with much reduced side
effects of radiation. Mice treated with a high radiation dose of
12 Gy had larger changes of body weight than those treated
with X-PDT at 4 Gy. It is also worth emphasizing that the X-
PDT exerted a notable profibrotic effect in the tumors, which
presented as the thickening of the peritumoral capsule and
accumulation of collagen in this capsule, as well as in the
central necrotic areas, which were more pronounced than in
other treatment groups.
In summary, our strategy may offer a paradigm-shifting
treatment alternative for patients who need neoadjuvant
radiotherapy but wish to avoid the long-term detrimental
effect on functional outcome by undergoing X-PDT technique
which used only a fraction of the conventional radiotherapy.
Our engineered nanocarriers are made from clinically approved
components using a simple synthesis method. Their rational
design avoids the need for numerous manufacturing steps in
future scaling-up processes. This formulation will also enable
rapid translation to the clinic.
■ MATERIALS AND METHODS
Materials. Dichloromethane (DCM), VP, dodecanethiol-
stabilized gold nanospheres (2% (w/v) in toluene), poly(vinyl
alcohol) (PVA, MW: 31 000−50 000), (4-carboxybutyl)-
triphenylphosphonium bromide (TPP−COOH), N-hydroxy-
succinimide (NHS), 1-ethyl-3-(3-(dimethylamino)propyl)-
carbodiimide (EDC), and Triton X-100 were purchased
from Sigma-Aldrich Australia. NH2−PEG−PLGA (MW:
12 000:5000 Da) was purchased from Akina, Inc. Singlet
oxygen sensor green (SOSG) was obtained from Thermo
Fisher Scientific Inc. CellTiter 96 AQueous One Solution Cell
Proliferation Assay was purchased from Promega. Muse
Annexin V and Dead Cell Assay was purchased from Merck
Millipore. Primary antibodies (against ERK, p-ERK, Akt, p-
Akt, BAX, BAD, Bcl-2, and cleaved caspase-3) and HRP-
conjugated secondary antibody were purchased from Cell
Signaling Technology. Enhanced chemiluminescence reagents
were obtained from Thermo Fisher Scientific.
Synthesis of PLGA Nanocarriers and PLGA−TPP
Conjugates. PLGA nanocarriers with varying amounts of
gold nanoparticles and a fixed amount of VP were synthesized
via a solvent evaporation single-emulsion method.42 Briefly,
300 μL of DCM solution containing VP (2.3 mg/mL) was
added to 2.5 mL of DCM solution containing 15 mg of PLGA
and mixed with the gold nanoparticle suspension (molar ratio
of gold to VP from 0:1 to 10:1). The mixture was added
dropwise to an aqueous PVA (1%, w/w) solution and
sonicated for 1.5 min at 200 W using a microtip probe
sonicator (Branson Digital Sonifier, S-250D, Emerson
Industrial Automation). The solvent was evaporated overnight
at room temperature, under moderate magnetic stirring. PLGA
nanocomposites were purified by centrifugation (10 min, 7500
rpm) and washed 3× with distilled water. The final product
was suspended in 1 mL of distilled water as stock solution for
further use. For nanocarrier conjugation with TPP−COOH,
we used a well-established NHS-EDC method.43 Briefly, 10 mg
of TPP−COOH was dissolved with 1 mL of MES buffer (pH
= 5−6), followed by the addition of 21 mg of NHS and 36 mg
of EDC as covalent coupling reagents. The solution was kept
for 30 min at room temperature under stirring. After raising the
pH to 7.0−7.4, 200 μL of prepared NH2−PEG−PLGA was
added into the activated TPP solution. The mixture was
allowed to react for 4 h at room temperature under stirring.
Afterward, the PLGA−TPP conjugates were purified by
centrifugation (10 min, 7500 rpm) and washed with PBS
three times. No unusually high safety hazards were
encountered in the synthesis process.
Characterization. The extinction spectra of PLGA
conjugates containing VP were measured using a spectropho-
tometer (Cary 5000 UV−vis−NIR, Varian Inc.). The size
distribution and ζ potentials of the PLGA samples were
measured with a Zetasizer Nano Series instrument (Malvern
Instruments). The morphology of PLGA nanocarriers was
determined using transmission electron microscopy (TEM,
Philips CM10) and scanning electron microscopy (SEM, JEOL
JSM 7100F FESEM).
Singlet Oxygen Generation Test in the Solution and
VP Release from PLGA Nanocarriers. To quantify the
amount of 1O2 generated from PLGA samples containing gold
nanoparticles and VP with different molar ratios, 16 μL of
SOSG (0.5 mM) was mixed with 3 mL of PLGA suspension.
The mixture was then placed in a Petri dish and irradiated with
X-rays. A linear accelerator (6 MeV LINAC, Elekta AB) was
used to deliver different doses (1−4 Gy) to the samples. After
irradiation, the SOSG fluorescence at 525 at 488 nm excitation
was recorded using a Fluorolog-Tau-3 system. The increase of
SOSG fluorescence after irradiation was calculated as follows:
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where Fd and F0 are, respectively, the SOSG fluorescence
intensities at various X-ray irradiation doses and without
irradiation.
All PEGylated PLGA samples were dialyzed in Slide-A-Lyzer
MINI dialysis devices (Thermo Fisher Scientific). These
devices were then kept in 50 mL centrifuge tubes with 10
mL of PBS supplied with 10% (v/v) FBS at 37 °C for 24 h. An
aliquot of PBS was taken for fluorescence characterization of
the released VP at various time points. The total VP
fluorescence was measured by disrupting PLGA with DCM.
VP fluorescence (Ex/Em: 425 nm/690 nm) was recorded on a
Fluorolog-Tau-3 system. The percentage of VP release










where Ft and F0, respectively, indicate the fluorescence
intensity of VP at various incubation time points and before
incubation. Fmax refers to the total fluorescence intensity of VP
after the disruption of PLGA samples by adding DCM.
Cell Preparation. Human colon adenocarcinoma HCT
116 cells and normal human colon epithelial cells (CCD 841
CoN) were purchased from the American Type Culture
Collection. HCT 116 cells were cultured in McCoy’s 5A
(modified) medium; CCD 841 CoN cells were cultured in
Eagle’s minimum essential medium (EMEM). All culture
media were supplemented with 10% (v/v) FBS and 1% (v/v)
antibiotic−antimycotic. The flasks were maintained in a 37 °C
incubator with 5% (v/v) CO2 humidified air. The cells were
detached with trypsin and transferred at appropriate dilutions
into 96-well plates for cell viability assays or glass-bottom Petri
dishes for cell imaging. For X-ray radiation experiments, the
cells were radiated by using the same accelerator as described
in the singlet oxygen generation section.
Colocalization of PLGA−TPP Conjugates with Mito-
chondria. HCT116 cells were seeded on a glass-bottom Petri
dish at a concentration of 1 × 105 cells/mL for 48 h. After that,
the cells were incubated with PLGA−TPP suspension (100
μg/mL) for 4 h. After three washes with PBS, the cells were
costained with MitoTracker Red (200 nM, Thermo Fisher
Scientific) and NucBlue Live ReadyProbes reagent (Thermo
Fisher Scientific) in live cell imaging solution at 37 °C for 30
min. The cells were then washed three times with PBS and
kept in the live cell imaging solution for confocal imaging using
a Leica SP2 confocal laser scanning microscopy system. Laser
sources at 405 and 488 nm were used for the excitation of VP,
NuBlue, and MitoTracker, respectively. Colocalization be-
tween TPP-conjugated nanocarriers and lysosomes was
determined by using LysoTracker Red DND-99 (200 nM,
Thermo Fisher Scientific) under the same experimental
conditions. The Lysotracker was excited at 580 nm.
Intracellular Singlet Oxygen Detection. HCT116 cells
were cultured in glass-bottom Petri dishes at 1 × 105 cells/mL.
When the cells reached 70−80% confluency, they were treated
in different conditions, including incubation with the PLGA
nanocarriers alone (50 μg/mL), TPP−PLGA nanocarriers
alone (50 μg/mL) for 4 h at 37 °C, radiation with 4 Gy alone,
PLGA + 4Gy, and PLGA−TPP + 4 Gy. In the cell groups
incubated with nanoparticles, the SOSG solution (5 μM) was
subsequently added to the cell medium at 3 h incubation time
point. For the cell group treated with X-ray alone, SOSG
solution was added to the cell medium for 1 h incubation and
washed out, followed by X-ray radiation. After the cells were
washed with fresh medium, the SOSG fluorescence signal
excited at 488 nm was imaged under a FV3000 confocal laser
scanning microscope at different time points. Quantitative
analysis of the SOSG signal was conducted by using ImageJ
software, which indicated the intracellular 1O2 level generated
under different experimental conditions.
Assessment on Mitochondria Membrane Potential
(ΔΨm). The HCT116 cells were, respectively, incubated with
PLGA−TPP (50 μg/mL) and nontargeted PLGA (50 μg/mL)
in the cell medium for 4 h, followed by X-ray radiation at 4 Gy.
The cells were then stained with 5 μM JC-1 dye (Thermo
Fisher Scientific) at 37 °C for 10 min per manufacturer’s
instructions and analyzed under a FV3000 confocal laser
scanning microscope at different time points. The ΔΨm
analysis was conducted using ImageJ software to calculate
the ratio of red-to-green channel intensity.
In Vitro Cytotoxicity Assays and Annexin V Assay. The
in vitro toxicity of X-PDT was evaluated using the MTS test.
Before MTS treatment, HCT 116 cells and CCD 841 CoN
cells (2 × 104 mL−1) were grown on 96-well plates in the
culture medium with 10% FBS for 24 h. After removing the old
media, the cells were incubated with PLGA−TPP samples
diluted in the culture medium for 4 h. After incubation, the old
medium was removed, and fresh medium was added, followed
by X-ray radiation at 4 Gy. The cytotoxicity of X-ray-induced
PDT on HCT 116 cells at 24 h was determined by the MTS
test (Promega Co., Fitchburg, WI) according to the
manufacturer’s instructions and compared with control cells
without any treatment. Cell viability was then calculated as a
percentage of the absorbance of the untreated control sample.
For a comparison, the viability of cells treated with PLGA−
TPP alone and X-ray at 4 Gy alone was also evaluated in the
same experimental conditions. HCT116 cells (1 × 105 cells/
well) were seeded in 25 cm2 cell culture flasks and treated with
X-ray alone, PLGA−TPP nanoparticles alone, and X-PDT. At
24 h after treatments, the cells were harvested from the culture
medium and washed with 1 mL of PBS, followed by the
addition of 100 μL of Muse Annexin V Dead Cell reagent.
Next, cells were incubated at room temperature for 20 min
without light. Apoptosis was then analyzed with Muse Cell
Analyzer and Muse analysis software (EMD Millipore).
Western Blotting Analysis. HCT116 cells were treated
with PLGA−TPP nanocarriers for 4 h alone, X-ray alone, or X-
PDT. After treatments, the cells were washed twice with PBS
and lysed with RIPA buffer (Thermo Fisher Scientific)
supplemented with a protease inhibitor cocktail (Thermo
Fisher Scientific) according to the protocol by the
manufacturer. Total protein was extracted and loaded in the
wells of Bis-Tris protein gel (Thermo Fisher Scientific). After
separation, the protein was transferred to PVDF membranes
(Thermo Fisher Scientific). The membranes were blocked
with a blocking buffer (Thermo Fisher Scientific) at 4 °C
overnight and and incubated with primary antibodies (against
ERK, p-ERK, Akt, p-Akt, BAX, BAD, Bcl-2, and cleaved
caspase-3) for 1 h at room temperature. All primary antibodies
were diluted 1:1000. After washing with blocker buffer three
times (Thermo Fisher Scientific), the membranes were
incubated with corresponding HRP-conjugated secondary
antibody for 1 h at room temperature. All secondary antibodies
were diluted 1:1000. After washing with blocker buffer three
ACS Central Science http://pubs.acs.org/journal/acscii Research Article
https://dx.doi.org/10.1021/acscentsci.9b01121
ACS Cent. Sci. 2020, 6, 715−726
723
times, the membranes were visualized using enhanced
chemiluminescence reagents on a ChemiDoc MP Imaging
System (Bio-Rad Laboratories, Inc.).
In Vivo Antitumor Effect Assessment of X-PDT. All
procedures were carried out in accordance with the guidelines
and approval of the Northern Sydney Local Heath District
Animal Ethics Committee (approval RESP/18/40). 6−7 week
old NOD scid gamma mice (The Animal Resources Centre,
Perth, Australia) were injected subcutaneously into the right
flank with 5 × 106 HCT 116 cells, suspended in a 100 μL
mixture of 50 μL of McCoy’s 5A (modified) medium and 50
μL of Matrigel. Tumors were measured regularly with a digital
calliper, and volume (V) was calculated by using the following
formula:
= × ×V L W1 2 ( )
2
where L and W are the length (large diameter) and width
(short diameter) of the tumor. When tumor volume reached
approximately 100 mm3, mice were randomly divided into 6
groups (4−5): Control without any treatment; PLGA−TPP, 4
Gy, and PLGA−TPP + 4, 8, and 12 Gy. PLGA−TPP
nanocarriers were given via intratumor injection at a dose of 10
mg/kg based on body weight. Under isoflurane anesthetic, CT
images were acquired at 60 kV, 0.8 mA, 1 mm aluminum
filtration using a small animal radiation research platform
(SARRP, Xstrahl, Inc., Suwanee, GA) and the subcutaneous
tumor selectively targeted for X-ray photon irradiation using
the MuriPlan Treatment Planning software (Xstrahl, Inc.,
Suwanee, GA). Radiation was stereotactically delivered using a
two beam anterior-posterior/posterior-anterior arrangement
(i.e., 0° and 180°) with a 10 × 10 mm collimator at 220 kV, 13
mA, 0.16 mm copper filtration, and dose rate 3.71 Gy/min
(Figure S11). CT imaging was conducted at every time point
the tumor measurements were recorded. The CT images were
analyzed using the Preclinical Imalytics software to display the
tumor morphology (Figure S11b). After completion of the
treatment, mice were observed for a further 2 weeks or until
the humane end point was reached. Body weight and tumor
volume were measured every 3 days. At the humane end point,
mice were sacrificed, and tumors were removed, photographed,
and fixed with 10% (v/v) neutral-buffered formalin for
histological analysis.
Histopathological Preparation of the Tumor Sam-
ples. Tumors were dissected together with adjacent normal
tissues and studied by histological, immunohistochemical, and
morphometrical methods. The samples were fixed in 10%
neutral buffered formalin, divided into two halves along the
long axis of the tumor, and embedded in paraffin blocks with
the internal tumor surface exposed. The samples were cut into
serial sections of 6 μm in thickness, deparaffinized, and stained
with hematoxylin and eosin (H&E) and by Masson’s trichrome
method (to reveal fibrotic reaction by blue collagen staining)
following conventional protocols. In order to examine the
mitotic activity indicative of proliferation in the tumors, the
sections were stained by immunohistochemical protocol
(IHC) for Ki-67 antigen expression using mouse−antihuman
monoclonal primary antibodies (MAB-4190, Sigma-Aldrich,
Australia; 1:200). IHC was performed using a heat-induced
epitope retrieval procedure in citrate buffer (pH 6.0) for 30
min in a water bath at 80 °C. The secondary HRP-conjugated
goat anti-Mouse IgG (H+L) cross-adsorbed antibody (G-
21040; Invitrogen, Australia; 1:1000) and DAB chromogen
were applied to detect the IHC staining.
Sample Slide Imaging and Data Analysis. The
histological preparations were examined by two trained
pathologists blinded to animal treatment. The H&E images
were obtained using an Aperio XT slide scanner (Leica,
Germany) equipped with dry-air objective 20×/N.A. 0.75
objective with a 2× magnification changer and a CCD digital
8/10-bit monochrome TDI line-image capture camera
(resolution of 0.25 μm/pixel.) For the classification of live
tumor and necrotic areas, the scanned images of H&E-stained
samples were segmented by using K-means clustering.44 K
means clustering is an unsupervised machine learning approach
which can identify different colors in an image while ignoring
variation in their brightness.45 The areas dominated by purple
color (hematoxylin staining of cellular nuclei) were identified
as live tumor; the areas with prevailing pink color (eosin
staining of cytoplasm of nuclei-free dead cells) were classified
as the nonviable parts. The combination of the live and
necrotic tumor areas was defined as the whole area of the
sample section. The relative area of live tumor on the sections,
ω, was measured as a part of the whole tumor section which
was accepted equal as 1. The measurements of ω were
averaged across each tumor sample. The estimated volume of
live tumor in each sample was calculated by using the following
formula:
ω= ×V Vl
where Vl is an estimated volume of live tumor, V is a tumor
volume obtained by calliper measurements as described above,
and ω is a relative area classified as live tumor.
The single-frame/field of view images of H&E, Masson’s
trichrome, and IHC-stained samples were obtained with the
use of an upright research BX53 microscope (Olympus)
equipped with Plan Apochromat 4×/NA 0.16, 20×/NA0.75,
40×/NA0.95, and oil-immersion 100×/NA1.4 objectives
(Olympus). Images were recorded using a digital DP80
camera (1360 × 1024 pixels, Olympus). The relative areas of
the viable and nonviable (paranecrotic and necrotic) tumor
tissues were measured using ImageJ open source software, and
the obtained morphometry results were statistically analyzed
with nonparametric tests (Kruskall−Wallis H test, followed by
Mann−Whitney U test) by SPSS 13.0 for Windows.
Statistical Analysis of Other Data (Excluding Histo-
logical Analysis). Data represent at least three independent
experiments and are presented as the mean ± SD. Statistical
analyses were performed using GraphPad Prism 7.0 software,
and comparisons were made by the two-way ANOVA test for
tumor size and log-rank test for survival curve. P-values of less
than 0.05 were considered statistically significant.
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